The clinical efficacy and safety of intravenous levofloxacin in the treatment of 4888 patients with bacterial infections: a multi-center trial
Abstract
OBJECTIVE: To evaluate the clinical efficiency and safety of intravenous levofloxacin in the treatment of bacterial infections at a dose of 500 mg once a day.
METHODS: Randomized, prospective, multicenter, open-label study.
RESULTS: The total effective rate of levofloxacin was 90.8% (4103/4521). The effective rates of levofloxacin in the treatment of bacterial infections of respiratory tract, urinary tract, digestive tract and gynecologic infections and infections complicated with hematological disease were 90.2% (2884/3198), 92.3% (810/878), 91.9% (203/221), 94.5% (120/127), 88.7% (86/97), respectively. The bacterial eradication rate was 80.3% (677/843). The most common adverse drug reactions were gastrointestinal disorders (3.9%, 193/4888) and local irritation (1.7%, 84/4888), which were mild and disappeared after stopping administration.
CONCLUSION: Intravenous levofloxacin with a dose of 500 mg once a day is effective and safe in treating bacterial infections with low adverse reactions.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.